The pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are immense - and soaring. So why are safety and pharmacovigilance departments lagging in their application of smart technology, wonders John Price, a life sciences regulatory and safety consultant and advisor to Arriello.

Streamlining Pharmacovigilance : Why the Inertia? via Pharmaceutical Executive and Arriello's Director of Drug Safety Peter Kohut analyse the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.